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Genome-wide association of polycystic ovary
syndrome implicates alterations in gonadotropin
secretion in European ancestry populations
M. Geoffrey Hayes1,2,3,*, Margrit Urbanek1,2,*, David A. Ehrmann4, Loren L. Armstrong1, Ji Young Lee1, Ryan Sisk1,
Tugce Karaderi5, Thomas M. Barber6, Mark I. McCarthy5,7,8, Stephen Franks9, Cecilia M. Lindgren5,10,
Corrine K. Welt11, Evanthia Diamanti-Kandarakis12, Dimitrios Panidis13, Mark O. Goodarzi14, Ricardo Azziz15,
Yi Zhang16,17, Roland G. James16,17, Michael Olivier18, Ahmed H. Kissebah16,17,z, Reproductive Medicine
Network#, Elisabet Stener-Victorin19, Richard S. Legro20,**, Andrea Dunaif1,2,**
Polycystic ovary syndrome (PCOS) is a common, highly heritable complex disorder of
unknown aetiology characterized by hyperandrogenism, chronic anovulation and defects in
glucose homeostasis. Increased luteinizing hormone relative to follicle-stimulating hormone
secretion, insulin resistance and developmental exposure to androgens are hypothesized to
play a causal role in PCOS. Here we map common genetic susceptibility loci in European
ancestry women for the National Institutes of Health PCOS phenotype, which confers the
highest risk for metabolic morbidities, as well as reproductive hormone levels. Three loci
reach genome-wide signiﬁcance in the case–control meta-analysis, two novel loci mapping to
chr 8p32.1 and chr 11p14.1, and a chr 9q22.32 locus previously found in Chinese PCOS. The
same chr 11p14.1 SNP, rs11031006, in the region of the follicle-stimulating hormone B poly-
peptide (FSHB) gene strongly associates with PCOS diagnosis and luteinizing hormone levels.
These ﬁndings implicate neuroendocrine changes in disease pathogenesis.
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P
olycystic ovary sydrome (PCOS) is a common disorder of
premenopausal women affecting 7–15% of this population
worldwide1. It is diagnosed by its reproductive phenotype
of hyperandrogenism, ovulatory disturbances and polycystic
ovarian changes. PCOS is also frequently associated with
insulin resistance, pancreatic b-cell dysfunction and obesity that
confer a signiﬁcantly increased risk for type 2 diabetes (T2D)1.
The aetiology of PCOS is unknown. Anovulation and
hyperandrogenism are a consequence primarily of disordered
gonadotropin secretion1. Increased LH stimulates ovarian
testosterone (T) production while relative FSH deﬁciency
results in arrest of ovarian folliculogenesis2. There may also be
constitutive increases in ovarian and adrenal androgen secretion1.
Increased T levels feedback on the hypothalamus contributing to
disordered gonadotropin release3. Androgen administration
during critical developmental windows produces phenocopies of
PCOS in animal models suggesting that this mechanism may also
be operative in humans4. Finally, insulin resistance and the
resulting hyperinsulinemia contribute to both hyperandrogenism
and ovulatory dysfunction1.
In addition, there are abnormalities in the gonadotropin-
independent development of preantral follicles in polycystic
ovaries (PCO) resulting in an excess of primary follicles
compared to normal ovaries2. Decreased follicular atresia in
PCO may contribute to this ﬁnding2. However, 20–30% of
women with regular menses and no reproductive symptoms have
PCO morphology (PCOM)5. PCOM is more common in younger
women5. Even in the absence of hormonal features of the
syndrome, women with PCOM have increased sensitivity to
exogenous gonadotropin administration6.
As the precise cause(s) of PCOS remains elusive, there has been
substantial controversy surrounding the most appropriate
diagnostic criteria1. The ﬁrst diagnostic criteria, the so-called
National Institutes of Health (NIH) criteria, required clinical or
biochemical evidence of hyperandrogenism and chronic
anovulation with the exclusion of speciﬁc conditions that can
present with similar features1. The Rotterdam criteria7 added
PCOM as a criterion and required two of three of these features
for the diagnosis of PCOS. This modiﬁcation resulted in multiple
phenotypes of affected women, including those with PCOM
and hyperandrogenism but no anovulation and those with
anovulation and PCOM but no hyperandrogenism. The
Androgen Excess Society criteria8 modiﬁed the Rotterdam
criteria to require hyperandrogenism for the diagnosis of PCOS
thereby removing the anovulation and PCOM phenotype. There
is now general agreement that the NIH criteria identify the
phenotype at greatest risk for insulin resistance and its associated
metabolic features, whereas the other phenotypes have only
minimal metabolic risk1,9.
Familial aggregation of PCOS and its associated features10,11 as
well as twin studies12 have suggested that genetic factors play an
important role in disease pathogenesis. Further, two or more
phenotypes can be present in the same family suggesting some of
these phenotypic differences reﬂect variable expression and/or
penetrance of the same gene10. Several susceptibility loci for PCOS
have been reproducibly mapped in family-based13 and genome-
wide association studies14,15. Previous PCOS genome-wide
association studies (GWAS) have been limited to Asian cohorts
diagnosed using the Rotterdam criteria14–16. PCOS cohorts thus
identiﬁed have multiple phenotypes of affected women8. Therefore,
it has not been possible to determine whether the genetic
architecture of PCOS varies by phenotype. Further, there have
been no genome-wide quantitative trait analyses to assess potential
genetic contributions to the hormonal features of the syndrome.
The aim of our study is to identify susceptibility loci for the
NIH phenotype of hyperandrogenism and anovulation, which is
associated with high risk for insulin resistance and dysglycemia1,9,
and its quantitative reproductive hormone levels17. We perform a
discovery GWAS (Stage 1) of 984 PCOS cases and 2,964
population controls followed by replication (Stage 2) in 1,799
PCOS cases and 1,231 phenotyped reproductively normal control
women. We follow this with a second replication (Stage 3) of the
top 24 associations after a meta-analysis of stage 1 and 2 in a
cohort of 217 PCOS cases and 1,335 population controls. Three
loci reach genome-wide signiﬁcance in the case–control meta-
analysis of all three strata; two novel loci, chr 8p32.1 in the region
of GATA4 and NEIL2 and chr 11p14.1 in the region of the
follicle-stimulating hormone B polypeptide (FSHB) gene, and one
previously found in Chinese PCOS15, chr 9q22.32 in the region of
c9orf3/FANCC. The same chr 11p14.1 SNP, rs11031006, in the
region of the FSHB gene also reaches genome-wide signiﬁcance in
the meta-analysis of the quantitative luteinizing hormone (LH)
levels. These ﬁndings implicate gonadotropins in the patho-
genesis of PCOS.
Results
Case–control analysis. Three loci were associated with PCOS in
our cohort (Table 1) at a genome-wide signiﬁcant threshold after
Stage 3: the 8p32.1 GATA4/NEIL2 locus, the 9q22.32 c9orf3/
FANCC locus, and 11p14.1 FSHB/ARL14EP locus with sample-
size weighted three-strata meta-analyses Pmeta-all¼ 8.0 10 10;
Pmeta-all¼ 4.6 10 13; and Pmeta-all¼ 1.9 10 8, respectively
(Table 2; Figs 1a and 2a–c; Supplementary Data 1–2).
The 8p32.1 PCOS locus spanned a 6.6 region of extensive
linkage disequilibrium (r240.2) including the 30 end of GATA4
and all of NEIL2 into the intergenic region before FDFT1. The
most strongly associated SNP (rs804279) was intergenic,
approached genome-wide signiﬁcance in the Stage 1 Discovery
GWAS (A allele, OR¼ 0.74, 0.66–0.83 95%CI, logistic regression
P¼ 1.4 10 6), and was nominally signiﬁcant in the Stage 2
Metabochip Replication (A allele, OR¼ 0.82, 0.73–0.93 95%CI,
logistic regression P¼ 2.7 10 3) for a sample-size weighted
two-strata meta-analysis Pmeta¼ 1.9 10 8. The additional UK
Replication (Stage 3) was nominally signiﬁcant (A allele,
OR¼ 0.74, 0.58–0.94 95%CI, logistic regression P¼ 0.013) for a
sample-size weighted three-strata meta-analysis Pmeta-All¼ 8.0
 10 10. The proportion of heritability explained by this SNP
was 0.79% (ref. 18). After conditioning on the lead SNP in the
region, the association was reduced several log orders. This
pattern was consistent across all genome-wide signiﬁcant loci
suggesting that there was only one locus within each region of
interest discussed below (Supplementary Fig. 1).
The 9q22.32 PCOS locus spanned a B331.8 kb extensive
linkage disequilibrium (LD) region that includes c9orf3, FANCC
and a number of micro RNA genes. The most strongly associated
SNP (rs10993397), in the large ﬁfth intron of c9orf3, reached
genome-wide signiﬁcance in the Stage 1 Discovery GWAS
(C allele, OR¼ 0.73, 0.66–0.81 95%CI, logistic regression
P¼ 2.2 10 8), was also nominally signiﬁcant in the Stage 2
Metabochip Replication (C allele, OR¼ 0.88, 0.79–0.98 95%CI,
logistic regression P¼ 2.4 10 4) for a sample-size weighted
two-strata meta-analysis Pmeta¼ 3.1 10 11. This SNP was
nominally signiﬁcant (C allele, OR¼ 0.72, 0.58-0.89 95%CI,
logistic regression P¼ 3.9 10 3) in the Stage 3 UK Replication
for a sample-size weighted three-strata meta-analysis Pmeta-
All¼ 4.6 10 13. The proportion of heritability explained by
this SNP was 0.79% (ref. 18). Rs10993397 was 61 kb upstream
from the previously identiﬁed intronic association in a Chinese
population15 but still within same the region of strong LD for
both European and Chinese ancestry. To test the independence of
the two loci, we conditioned the association of rs10993397 with
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Table 1 | Demographic characteristics of PCOS cases and controls in the GWAS and replication.
Cohort GWAS Replication
Age (years) BMI (kgm 2) Testosterone
(ngdl 1)
Age (years) BMI (kgm 2) Testosterone (ngdl 1)
Case Control Case Control Case Control Case Control Case Control Case Controls
PCOS Family
Study*
28 (24–32)
n¼ 718
— 35.5
(29.1–41.4)
n¼ 718
— 72 (59–91)
n¼663
— 28 (24–32)
n¼ 172
29 (24–33)
n¼ 105
35.0
(28.3–41.5)
n¼ 172
30.7
(23.3–35.0)
n¼ 105
70 (59–93)
n¼ 100
28 (17–35)
n¼ 35
63 (44–77)
n¼ 30
— 68 (49–86)
n¼47
25 (19–32)
n¼70
PPCOSI* 28 (26–30)
n¼64
— 35.3
(27.4–42.1)
n¼64
— 60 (44–82)
n¼62
— — — — — — —
University of
Chicagow
29 (25–34)
n¼ 202
— 36.2
(31.8–42.1)
n¼ 202
— 68 (52–93)
n¼202
— 27 (23–30)
n¼ 25
— 38.4
(32.4–42.7)
n¼ 25
— 64 (50–85)
n¼ 25
—
NUgene — 46 (34–58)
n¼ 2,964
— 25.0
(22.0–29.8)
n¼ 2,964
— — — — — — — —
Cedars–Sinai
Medical Centerz
— — — — — — 26 (22–31)
n¼ 130
37 (27–42)
n¼ 17
27.7
(22.5–33.9)
n¼ 130
24.6
(21.5–31.5)
n¼ 17
43 (31–62)
n¼ 121
23 (17–29)
n¼ 11
Massachusetts
General Hospital
— — — — — — 28 (24–32)
n¼472
25 (22–31)
n¼402
29.0
(23.9–37.0)
n¼472
23.0
(21.1–25.0)
n¼402
— —
Medical College
of Wisconsin*
— — — — — — — 38 (32–41)
n¼452
— 31.9
(24.2–38.9)
n¼452
— 19 (15–24)
n¼452
PPCOSII* — — — — — — 28 (26–31)
n¼ 265
— 35.1
(26.6–41.8)
n¼ 265
— 50 (37–67)
n¼ 265
—
University of
Alabama at
Birminghamy
— — — — — — 27 (22–33)
n¼ 193
32 (26–36)
n¼91
34.1
(27.8–40.8)
n¼ 193
23.7
(21.7–27.7)
n¼91
77 (63–94)
n¼ 193
44 (32–56)
n¼81
University of
Athens||
— — — — — — 23 (20–28)
n¼ 542
26 (23–34)
n¼ 164
24.5
(21.4–30.9)
n¼542
22.0
(20.1–24.5)
n¼ 164
72 (61–89)
n¼ 542
31 (25–43)
n¼ 163
Imperial College
London/
University of
Oxfordz
— — — — — — 32 (28–36)
n¼ 222
45 (45–45)
n¼ 1,335
28.4
(23.2–36.5)
n¼ 217
25.5
(23.0–29.4)
n¼ 1,335
69 (53–86)
n¼ 223
—
PCOS, polycystic ovary syndrome; BMI, body mass index; GWAS, genome-wide association studies. Data are expressed as median (25th–75th interquartile range). Hormone results are separated by
assay method when multiple methods and labs were used within a cohort, however the normal range was identical.
*Testosterone normal rangeo59ng dl 1
wTestosterone normal rangeo71 ng dl 1.
zTestosterone normal rangeo35 ng dl 1.
yTestosterone normal rangeo85 ng dl 1.
||Testosterone normal rangeo60ng dl 1.
zTestosterone normal rangeo70ng dl 1
Table 2 | Genome-wide signiﬁcant associations of PCOS and associated reproductive hormonal quantitative traits.
Stage 2 
(Metabochip replication) 
Stage
1 + 2 
meta-
analysis 
Stage 3 
(UK replication) 
Stage 1 
+ 2 + 3 
meta-
analysis
Trait Variant Chr Mb Gene or
Flanking 
Genes 
Eff EAF OR/ 
Beta*,†
95%
CI /
s.e.*
P Gen/ 
Imp
r 2 
EAF OR / 
Beta*,†
95% 
CI/ 
s.e.*
P Gen/ 
Imp 
r 2
Pmeta EAF OR/ 
Beta*,†
95% 
CI/ 
s.e.*
P Gen/ 
Imp r2
Pmeta-all
PCOS    rs804279      8    11.6 GATA4 / 
NEIL2 
A     0.74  0.74    0.66-
0.83 
1.4×10–6 0.99 0.74  0.82   0.73-
0.93
2.7×10–3  0.97  1.9×10–8  0.72   0.74    0.5   8-1.3×10–2 0.95 8.0×10–10
0.94
PCOS    rs10993397  9    97.7 C9orf3 C     0.44  0.73    0.66-
0.81 
2.2×10–8    1    0.44  0.88   0.79-
0.98
2.4×10–4    1      3.1×10–11 0.41  0.72    0.5   8-3.9×10–3 0.99 4.6×10–13 
0.89
PCOS    rs11031006  11  30.2 KCNA4 / 
FSHB 
G     0.15  1.41    1.24-
1.62 
7.8×10–8 Gen 0.16  1.18   1.02-
1.37
6.3×10–3   Gen  4.3×10–9  0.15  1.12     0.8   3-4.5×10–1 0.96 1.9×10–8
1.50
rs11031006  11  30.2 KCNA4 / 
FSHB 
G    0.20  3.19    0.53 1.8×10–9 Gen  0.21  2.19   0.657.7×10–4    Gen  8.5×10–12 0.15  0.60     0.12 1.8×10–6       0.96 2.7×10–16
Stage 1 
(Discovery GWAS) 
LH
CI, conﬁdence interval; EAF, effect allele frequency in cases and controls combined; Eff, effect allele; Gen, genotyped; FSH, follicle-stimulating hormone; Imp r2, Imputation r2; LH, luteinizing hormone;
PCOS, polycystic ovary syndrome; P value, signiﬁcance as assessed by logistic regressions (PCOS) or linear regressions (LH levels); Pmeta, signiﬁcance as assessed by sample-size weighted two-strata
meta-analyses (PCOS Stage 1: 984 cases & 2,964 population control women; PCOS Stage 2: 1,799 PCOS cases and 1,231 phenotyped reproductively normal control women (LH Stage 1: 645 PCOS cases;
LH Stage 2: 398 PCOS cases). Pmeta-all, signiﬁcance as assessed by sample-size weighted three-strata meta-analyses (Stages 1 and 2 as described for Pmeta; PCOS Stage 3: 217 PCOS cases and 1,335
population controls; LH Stage 3: 208 PCOS cases); OR, odds ratio.
*OR and 95% CI for dichotomous trait PCOS; Beta and s.e. for quantitative trait LH.
wUnits: LH: mIUml 1.
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PCOS on the lead Chinese GWAS locus in this region
(rs3802457). The association remained genome-wide signiﬁcant
after including the rs3802457 SNP as a covariate in the regression
model of PCOS and rs10993397, suggesting that the European
and Chinese ancestry speciﬁc loci in this region were independent
of one another (Supplementary Data 3).
The 11p14.1 PCOS locus spanned a 129.5 kb extensive LD
region beginning upstream of FSHB and continues through
ARL14EP (also known as C11orf46). The most strongly associated
SNP (rs11031006) for both PCOS approached genome-wide
signiﬁcance for PCOS in the Stage 1 Discovery GWAS (G allele,
OR¼ 1.41, 1.24–1.62 95%CI, logistic regression P¼ 7.8 10 8)
and was nominally signiﬁcant in Stage 2 Metabochip Replication
(G allele, OR¼ 1.18, 1.03–1.37 95%CI, logistic regression
P¼ 6.3 10 3) for a sample-size weighted two-strata meta-
analysis Pmeta¼ 4.3 10 9. This SNP was not signiﬁcant in the
Stage 3 UK Replication but trended in the same direction
as the Stages 1 and 2 (G allele, OR¼ 1.12, 0.83–1.50 95%CI,
logistic regression P¼ 0.45) for a sample-size weighted three-
strata meta-analysis Pmeta-All¼ 1.9 10 8. The proportion of
heritability explained by this SNP was 0.80% (ref. 18).
Quantitative trait analysis. The Stage 1 Discovery GWAS
for reproductive hormone levels within the PCOS cases
(N¼ 645–957 depending on hormone trait) identiﬁed three loci
reaching genome–wide signiﬁcance: the 7q33 DGKI locus with
total T levels, linear regression P¼ 1.3 10 8; the 10q26.11
CASC2 locus with FSH levels, linear regression P¼ 3.2 10 8;
and the 11p14.1 FSHB/ARL14EP locus with LH levels,
linear regression P¼ 1.8 10 9 (Table 2; Figs 1b and 2d;
SupplementaryData 1–2, Supplementary Figs 2–5). None of these
variants showed signiﬁcant association in the control women
(Supplementary Data 4). No genome-wide signiﬁcant associations
with dehydroepiandrosterone sulfate (DHEAS) or sex hormone
binding globulin (SHBG) levels were observed (Supplementary
Data 1; Supplementary Figs 6 and 7). The same 11p14.1
FSHB/ARL14EP SNP, rs11031006, that was most strongly
associated with PCOS reached genome-wide signiﬁcance with LH
in the Stage 1 Discovery GWAS (G allele, Beta¼ 3.19, 0.53 s.e.,
mIUml 1, linear regression P¼ 1.8 10 9) and was nominally
signiﬁcant in the Stage 2 Metabochip Replication (G allele,
Beta¼ 2.19, 0.65 s.e., mIUml 1, linear regression P¼ 7.7 10 4)
for a sample-size weighted two-strata meta-analysis Pmeta¼ 8.5
 10 12. The Stage 3 UK Replication was also nominally
signiﬁcant (G allele, Beta¼ 0.6, 0.12 s.e., mIUml 1, linear
regression P¼ 1.8 10 6) for a sample-size weighted three-
strata meta-analysis Pmeta-All¼ 2.7 10 16. The proportion of
phenotypic variance explained by this SNP was 5.4%. Upon
further investigation we determined this high proportion of
phenotypic variance explained was largely inﬂuenced by several
individuals with LH425mIUml 1 most likely measured mid-
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Figure 1 | Genome-wide association results for traits with genomewide signiﬁcant hits in the meta-analysis of GWAS and replication phases.
Manhattan plots for a. PCOS, b. LH levels. Alternating blue and red colours indicate genotyped SNPs, and accompanying black and grey colours indicate
imputed variants, on odd and even chromosomes, respectively. The red horizontal red line indicates genomewide signiﬁcance. QQ plots and lGC/ lGC1000
are inset in the upper right corner of each plot. For (a) PCOS, P values are from sample-size weighted two-strata meta-analysis of strata-speciﬁc
logistic regression P values (Stage 1: 984 cases and 2,964 population control women; Stage 2: 1,799 PCOS cases and 1,231 phenotyped reproductively
normal control women). For (b) LH levels, P values are from sample-size weighted two-strata meta-analysis of strata-speciﬁc linear regression P values
(Stage 1: 645 PCOS cases; Stage 2: 399 PCOS cases).
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cycle. Trimming the model to only include individuals with
LHo25mIUml 1 the association of rs11031006 with LH levels
increased in signiﬁcance (Stage 1 Discovery GWAS: Beta¼ 3.18,
0.53 s.e., mIUml 1, linear regression P¼ 2.0 10 9; Stage 2
Replication: Beta¼ 1.99, 0.42 s.e., mIUml 1, linear regression
P¼ 3.3 10 6; sample-size weighted two-strata meta-analysis
Pmeta¼ 3.4 10 14), and the proportion of phenotypic variance
explained was reduced to 2.3%.
The 7q33 T locus spans an 8.7 kb extensive LD region within
DGKI. The most strongly associated SNP (rs706560) reached
genome-wide signiﬁcance in the Stage 1 Discovery GWAS
(G allele, Beta ¼ 33.29, 5.85 s.e., ng dl 1, linear regression
P¼ 1.3 10 8). The proportion of phenotypic variance
explained by this SNP was 1.9%. The 10q26.11 FSH locus spans
a 6 kb extensive LD region that includes CASC2. The most
strongly associated variant (chr10:119956844:I) reached genome-
wide signiﬁcance in the Stage 1 Discovery GWAS (T allele,
Beta¼ 0.27, 0.05 SE, log10(mIUml 1), linear regression P¼ 3.2
 10 8). The proportion of phenotypic variance explained by
this variant was 0.1%. Neither of these SNPs passed imputation
quality thresholds in the Stage 2 Metabochip Replication cohort.
Further, chr10:119956844:I was not signiﬁcant in the Stage 3 UK
Replication (TCA allele, Beta ¼ 0.11, 0.47 s.e., ng dl 1, linear
regression P¼ 0.79), and no longer reached genome-wide
signiﬁcance in the combined meta-analysis (sample-size weighted
three-strata meta-analysis Pmeta-All¼ 7.3 10 7). Likewise,
rs706560 was not signiﬁcant in the Stage 3 UK Replication
(G allele, Beta ¼  0.71, 0.47 s.e., ng dl 1, linear regression
P¼ 0.15), and no longer reached genome-wide signiﬁcance in the
combined meta-analysis (sample-size weighted three-strata meta-
analysis Pmeta-All¼ 6.4 10 6).
Since BMI itself has a strong genetic component19, we explored
how our results changed when BMI was removed from the model
for the four genome-wide signiﬁcant loci (Supplementary Data 5).
The associations with all four loci (three with PCOS diagnosis, one
with LH levels) were only modestly different (less than 1.3 log
orders; two increase and two decrease, in linear regression
signiﬁcance) and all remained genome-wide signiﬁcant. Further
the odds ratios for the three PCOS loci changed only 0.01–0.02 in
Phase 1 and 0.02–0.07 in Phase 2, which is equivalent to 5.9%
change or less. The linear regression beta for the LH locus increased
11 and 22%, respectively, in Stage 1 and 2 when BMI is removed
from the model, which suggests that BMI moderately exacerbates
the effect of the 11p14.1 LH locus near FSHB on LH levels.
We performed an in silico look-up of the eQTLs for the
three genome-wide signiﬁcant loci using SCANdb (http://
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Figure 2 | Locuszoom plot of association results, linkage disequilibrium and recombination rates around the genome-wide signiﬁcant loci. (a) Chr. 9
PCOS locus (c9orf3/FANCC), (b) Chr. 11 PCOS locus (FSHB/ARL14EP), (c) Chr. 8 PCOS locus (GATA4/NEIL2), (d) Chr. 11 LH locus (FSHB/ARL14EP). In each,
the top panel reﬂects the meta-analysis results of the combined GWAS and replication phases. The LD estimates are colour coded as a heatmap from
dark blue (0Zr240.2) to red (0.8Zr241.0). Recombination hotspots are indicated by the yellow lines (recombination rate in cMMb-1 from HapMap
(http://hapmap.ncbi.nlm.nih.gov/downloads/recombination/2008-03_rel22_B36/rates/)). The bottom panel shows the genes and their orientation for each
region. For (a–c) PCOS loci, P values are from sample-size weighted two-strata meta-analysis of strata-speciﬁc logistic regression P values (Stage 1: 984 cases
and 2,964 population control women; Stage 2: 1,799 PCOS cases and 1,231 phenotyped reproductively normal control women). For (d) LH level locus, P values
are from sample-size weighted two-strata meta-analysis of strata-speciﬁc linear regression P values (Stage 1: 645 PCOS cases; Stage 2: 399 PCOS cases).
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www.scandb.org; Supplementary Data 6). The c9orf3 locus did
not have any eQTLs meeting nominal signiﬁcance (Po1 10 3)
as calculated by the QTDT. The GATA4/NEIL2 locus had
one eQTL meeting nominal signiﬁcance (NMUR1; QTDT P¼
7.0 10 5), and the FSHB/ARL14EP PCOS and LH level locus
had four eQTLs meeting nominal signiﬁcance (C20orf20, QTDT
P¼ 6.0 10 5, ARL6IP6, QTDT P¼ 7.0 10 5; CCDC69,
QTDT P¼ 1.0 10 4; and AGPAT2, QTDT P¼ 1.0 10 4).
All of these were detected in European populations (CEU) only.
None met a stringent threshold for genome-wide signiﬁcance.
Transcriptional analysis. There was strong evidence for tran-
scriptional activation as assayed by H3K36m3 and H3K4m3
signals in the chr 9q22.32 c9orf3/FANCC PCOS locus (Fig. 3a).
Marks indicative of transcriptional activation localized to the
50 end of FANCC and to a B100 kb region encompassing a
30 terminal transcript of C9orf3 plus a number uncharacterized
transcripts in all four ENCODE cell lines (adipose nuclei,
adult liver, pancreatic islets and skeletal muscle). Consistent with
these observations micro array analysis demonstrated robust
FANCC expression in the liver, pancreas, and, at low levels, in
skeletal muscle, and c9orf3 expression in pancreatic islets
and liver (GNF Expression Atlas 1 Human Data on Affy
U95 Chips http://genome.ucsc.edu). The RNAseq tracks
(http://genome.ucsc.edu; Fig. 4a) demonstrated virtually universal
expression of FANCC, as well as HIATl1, although the latter is
outside the bounds of extensive LD from the lead SNP in the
region (Fig. 2a).
The chr 8p32.1 PCOS locus was transcriptionally active in
adipose nuclei, adult liver, skeletal muscle and pancreatic islets.
NEIL2 and FDFT1 had evidence for promoter activity via
H3K4m3 and H3K9ac binding and evidence of actively
transcribed regions via H3K36m3 signals (Fig. 3c). FDFT1 was
expressed at low levels in adipocytes and pancreatic islets and
GATA4 was expressed at low levels in liver and pancreatic islets in
microarray analysis (GNF Expression Atlas 1 Human Data on
Affy U95 Chips http://genome.ucsc.edu). RNAseq (Fig. 4c)
showed absence of expression levels for GATA4, inconsistent
expression levels of NEIL2, and high expression levels of FDFT1
and CTSB, although the latter is outside the bounds of extensive
LD from the lead SNP in the region (Fig. 2c).
The most promising functional candidate gene was the
FSHB/ARL14EP PCOS and LH levels locus mapping to chr
11p14.1. FSHB showed no evidence for transcriptional activation
in the selected ChipSeq ENCODE (Fig. 3b) or RNAseq cell lines
(Fig. 4b), which do not include pituitary tissues. Microarray
analysis detected FSHB expression predominantly in the pituitary,
with low levels detected in adipocytes and the pancreas.
Furthermore, ARL14EP had evidence for promoter activity
(H3K4m3 and H3K9ac) in all four ENCODE cell lines and for
actively transcribed genes (H3K36m3) in all cell lines except
pancreatic islets. ARL14EP was expressed at universally high
levels with RNAseq in the cell types shown in Fig. 4b but the
microarray analysis detected ARL14EP only at low levels in
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Figure 3 | ENCODE histone mark proﬁle for genomewide signiﬁcant
PCOS and LH level GWAS loci (http://www.roadmapepigenomics.org/
data). Methylation marks in four PCOS relevant human tissue mapping to:
(a) Chr. 9 PCOS locus (c9orf3/FANCC), (b) Chr. 11 PCOS and LH level locus
(FSHB/ARL14EP) and (c) Chr. 8 PCOS locus (GATA4/NEIL2). Each is a
schematic of the genomic region including diagrams of genes mapping to
the region. ChipSeq signal tracks for each tissue (AN, adipose nuclei; AL,
adult liver; PI, pancreatic islets; SM, skeletal muscle) for six histone marks
(H3K27m3, H3K36m3, H3K4m1, H3K4m3, H3K9ac and H3K9m3) are
labelled to the left of the panel.
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adipocytes (GNF Expression Atlas 1 Human Data on Affy U95
Chips http://genome.ucsc.edu).
Histone mark and mRNA level ENCODE data for the
unreplicated 7q33 T (DGKI) locus and 10q26.11 FSH (CASC2)
locus are presented in Supplementary Figs. 8-9.
Discussion
PCOS is a complex genetic disease characterized by disordered
gonadotropin secretion, hyperandrogenism, PCO and insulin
resistance1. Each of the biochemical features has been
hypothesized to play a causal role in the development of
PCOS1,4. There are multiple affected phenotypes depending on
the diagnostic criteria applied1,8. We undertook this study to
investigate genetic loci associated with the NIH phenotype of
PCOS that confers the highest risk for metabolic morbidities,
including T2D and metabolic syndrome1,9. Three loci reached
genome-wide signiﬁcance in the PCOS case–control meta-
analysis, two novel loci, chr 8p32.1 GATA4/NEIL2 and chr
11p14.1 FSHB/ARL14EP, and a chr 9q22.32 c9orf3/FANCC locus
previously found in Chinese PCOS. The lead SNP at the same
novel 11p14.1 FSHB/ARL14EP locus, rs11031006, was strongly
associated with LH levels in addition to PCOS diagnosis. These
ﬁndings suggest that genetic variation in FSH plays an important
role in the aetiology of PCOS in European ancestry women with
the NIH phenotype.
FSHB encodes the FSH beta polypeptide20, a member of a
family of glycoprotein hormones that includes LH, TSH and
hCG, and consists of a common alpha subunit and a hormone-
speciﬁc beta subunit21. FSH plays a central role in the regulation
of ovarian folliculogenesis, which is disordered in PCOS2, in part
due to a relative decrease in FSH secretion. LH regulates theca cell
T synthesis and increased ovarian androgen production in PCOS
is LH-dependent1. Adjusting for LH levels in the regression
model between rs11031006 and PCOS negated the association
(OR¼ 1.18, 1.02–1.37 95%CI, P¼ 6.3 10 3 without LH in the
model; OR¼ 1.55, 1.01–2.39 95%CI, P¼ 0.66 with LH in the
model; Supplementary Data 7), suggesting that the association
with FSHB is mediated by LH. These ﬁndings suggest that
variation in FSHB contributes to the cardinal gonadotropin
secretory changes characteristic of PCOS22. Indeed, an FSHB
promoter polymorphism has been associated with higher
circulating LH and lower circulating FSH levels in men23,
analogous to characteristic changes in gonadotropin levels in
PCOS1. This polymorphism is also associated with reduced
sperm counts23. It remains possible that other genes in LD
with the 11p14.1 signal, such as ARL14EP, which encodes ADP-
ribosylation factor-like 14 effector protein that may function to
control the movement of MHC class II-containing vesicles24,
contribute to PCOS pathogenesis. Additional ﬁne-mapping and
functional studies will be needed to resolve this issue.
The second novel locus associated with European PCOS was
8p32.1 in the region of GATA4 and NEIL2. GATA4 encodes a
zinc-ﬁnger transcription factor that regulates gonadal develop-
ment and the transcription of steroidogenic genes. Deletion of
GATA4 results in abnormal responses to exogenous gonadotro-
pins and impaired fertility in mice25. GATA4 is expressed in
PCOS ovarian follicles but this expression does not differ from
control follicles26. However, the expression of another member of
this family, GATA6, is increased in PCOS theca cells27. NEIL2
encodes nei endonuclease VIII-like 2, a member of a class of
DNA glycosylases involved in the repair of DNA damage28. The
8p32.1 locus also encompasses the promoter region of FDFT1
that encodes farnesyl-diphosphate farnesyl transferase, the ﬁrst
speciﬁc enzyme in the cholesterol biosynthesis pathway and thus
also critical for testosterone biosynthesis. FDFT1 is associated
with nonalcoholic fatty liver disease29.
We also replicated the 9q22.32 c9orf3/FANCC PCOS locus
previously reported in Han Chinese15, although the Chinese and
European loci were independent of one another (Supplementary
Data 3). Multi-ethnic ﬁne-mapping will be required to tease this
apart further. One gene in this region, c9orf3, encodes a member
of the M1 zinc aminopeptidase family, aminopeptidase O (AP-
O)30. AP-O is expressed in the pancreas, placenta, liver, testis and
heart where it is postulated to play a role in proteolytic processing
of biologically active peptides, for example, the cleavage of
angiotensin III to generate angiotensin IV30. FANCC encodes the
protein for Fanconi anaemia complementation group C protein
(FANCC) that functions in complexes to repair DNA cross-
linking damage, and also suppresses apoptosis31.
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Figure 4 | ENCODE mRNA levels for genome-wide signiﬁcant PCOS and
LH level GWAS loci (http://www.roadmapepigenomics.org/data).
RNAseq levels in four PCOS relevant human tissue mapping to the (a) Chr.
9 PCOS locus (c9orf3/FANCC), (b) Chr. 11 PCOS and LH level locus (FSHB/
ARL14EP) and (c) Chr. 8 PCOS locus (GATA4/NEIL2). Each is a schematic of
the genomic region including diagrams of genes mapping to the region.
Sources of RNA are labelled to the left of the panel.
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Further, we nominally replicated (Po0.05), in the same
direction, seven of the eleven previously identiﬁed Chinese PCOS
SNPs (Table 3), including gonadotropin receptor genes LH/CGR
and FSHR, as well as THADA, DENND1A, YAP1, and RAB5B/
SUOX14,15, exceeding the number of associations we would
expect to replicate by chance alone. We did not replicate the
previously identiﬁed 8q24.2 Korean PCOS locus (Table 3)16.
However, this GWAS in Korean women with the Rotterdam
PCOS phenotypes failed to replicate any of the European or
Chinese PCOS loci at a signiﬁcance level of 10 5 or higher16. The
failure to replicate these loci could be due to a lack of power in the
Korean study or to differences in the phenotypes studied,
although both the Chinese and Korean GWAS used the
Rotterdam diagnostic criteria.
Two quantitative hormone level loci, in addition to the 11p14.1
FSHB/ARL14EP LH locus, were genome-wide signiﬁcant in the
Stage 1 Discovery GWAS of quantitative hormone levels: the7q33
T locus, in the region of DGKI, and the 10q26.11 FSH locus, in the
region of CASC2. They failed quality control in the Stage 2
Metabochip Replication cohort and did not demonstrate signiﬁcant
associations in the Stage 3 UK Replication cohort. After inclusion
of the Stage 2 and 3 replication data, the meta-analysis across all
three strata no longer reached genome-wide signiﬁcance for these
two loci. Further, the locuszoom plot (Supplementary Fig. 5) for
the 10q26.11 FSH locus (CASC2) indicates only a single variant in
the region was strongly associated (Po10 4), potentially indicat-
ing poor imputation of this indel, although the imputation r240.9.
Therefore, these ﬁndings should be considered tentative, and will
require further testing in additional cohorts. DGKI, diacylglycerol
kinase iota, is a member of the type IV diacylglycerol kinase
family32. CASC2, cancer susceptibility candidate 2, has been
associated with endometrial cancer33.
A GWAS of T and sex hormone binding globulin (SHBG)
levels in men34 found an association between variants in the
SHBG gene and these quantitative hormone levels. We replicated
the ﬁndings for rs12150660 (Supplementary Table 8) with both T
and SHBG levels, but not at genome-wide signiﬁcant thresholds.
We could not attempt to replicate the associations with rs6258 as
the genotype data for that SNP did not pass quality control
thresholds in our study. As the mean and range of T levels in both
PCOS and control women were much smaller (approximately
one-tenth that in men), this may have limited the ability to detect
associations identiﬁed in men34.
Increased BMI is commonly associated with PCOS, particularly
in US cohorts of European ancestry1. Accordingly, we adjusted
for BMI in our model to reduce the chance of identifying BMI-
related rather than PCOS-related loci. However, removing BMI
from the model had minimal impact on our results. All four
genome-wide signiﬁcant loci (three PCOS diagnosis associated,
one LH levels associated) were genome-wide signiﬁcant with or
without the inclusion of BMI as a covariate. Removing the BMI
covariate led to evenly split number of increases and decreases in
signiﬁcance, and the effect sizes changed o6%. We also did not
ﬁnd any evidence for genome-wide signiﬁcant associations with
PCOS of variants in known obesity or type 2 diabetes genes.
Collectively, these ﬁndings suggest that while BMI is associated
with PCOS, genes involved in BMI have little impact on the
genetics of PCOS.
The heritability of PCOS is B70% in monozygotic twin
studies12. However, the portion of heritability accounted for by
the three PCOS loci were small (o1% each) as has been observed
with other common complex diseases and traits35. Although we
now count fourteen replicated genome-wide signiﬁcant PCOS
loci across Chinese14,15 and European36–38 ancestry populations
including those identiﬁed in this study, each has relatively small
effect sizes that when taken collectively only account for a small
portion of the heritability of PCOS as estimated from twin
studies. Investigations of the genome-wide genetic architecture39
of PCOS should increase this, but other variables (for example,
structural variants, epigenetic factors, epistasis and so on) likely
account for the remaining heritability.
We assessed the transcriptional potential of the three PCOS
GWAS loci using three independent methods. Each of the three
methods capture slightly different data on transcription potential
and have different sensitivities to detect transcription40,41. Data
from the two sequencing-based data methods (ChIP-Seq and
RNASeq) are more congruent with each other than either are
with data from the expression arrays (GNF Expression Atlas 1
Human Data on Affy U95 Chips http://genome.ucsc.edu).
Further, the results for any given tissue or cell line are derived
from a single individual and thus do not take into account inter
individual variation in gene expression (http://genome.ucsc.edu).
With these caveats in mind, each of the genomic regions
identiﬁed in our GWAS was shown to be transcriptionally active
in at least one tissue that is affected in PCOS. These ﬁndings are
consistent with these genomic regions harbouring PCOS
susceptibility genes, although clearly further studies in tissues
relevant to the PCOS reproductive phenotype are needed.
Our study was limited to women with the NIH phenotype of
PCOS that is deﬁned by endocrine features rather than PCOM.
Table 3 | Genetic association results of variants identiﬁed in previous PCOS GWAS.
Asian GWAS Stage 1 Discovery GWAS Stage 2 Metabochip Replication Stage 1þ 2
Meta-Analyses
Trait SNP Chr Mb Gene or
Flanking
Genes
Eff Non-
Eff
OR P value Ref EAF OR 95%CI P value Gen/
Imp r2
EAF OR 95%CI P value Gen/
Imp r2
Pmeta
PCOS rs12468394 2 43.5 THADA C A 0.72 1.59 10 20 14 0.5 0.88 0.80–0.98 7.61 1002 0.97 0.49 0.97 0.87–1.08 4.80 1003 Gen 1.51 1003
PCOS rs12478601 2 43.7 THADA C T 0.72 3.48 10 23 14 0.57 0.91 0.82–1.00 1.43 1001 Gen 0.58 1 0.9–1.11 9.26 1002 1 2.76 1002
PCOS rs13405728 2 48.9 LHCGR A G 0.71 7.55 10 21 14 0.06 0.74 0.59–0.94 3.65 1002 0.97 0.06 0.81 0.65–1.02 4.03 1002 0.93 3.50 1003
PCOS rs2268361 2 49.2 FSHR C T 0.87 9.89 10 13 15 0.63 0.88 0.80–0.98 9.61 1002 Gen 0.6 0.84 0.76–0.94 1.76 1001 0.93 3.19 1002
PCOS rs4385527 9 97.6 C9orf3 G A 0.84 5.87 109 15 0.41 0.77 0.70–0.86 1.53 1006 Gen 0.42 0.89 0.8–0.99 9.51 1004 Gen 6.39 1009
PCOS rs3802457 9 97.7 C9orf3 G A 0.77 5.28 10 14 15 0.02 0.65 0.45–0.95 3.50 1002 0.91 NA NA NA NA NA 3.50 1002
PCOS rs10818854 9 126.4 DENND1A G A 1.51 9.40 10 18 14 0.05 1.26 1.02–1.56 1.77 1003 0.99 0.05 1.45 1.13–1.86 6.89 1002 0.95 3.66 1004
PCOS rs10986105 9 126.5 DENND1A T G 1.47 6.90 10 15 14 0.05 1.3 1.04–1.63 4.05 1004 1 0.05 1.69 1.3–2.2 1.71 1003 0.98 2.30 1006
PCOS rs1894116 11 102 YAP1 A G 1.27 1.08 10 22 15 0.1 1.15 0.97–1.35 1.46 1002 Gen NA NA NA NA NA 1.46 1002
PCOS rs705702 12 56.3 RAB5B /
SUOX
A G 1.27 8.64 10 26 15 0.32 1.17 1.05–1.30 1.15 1002 0.98 0.32 0.97 0.86–1.09 6.09 1001 0.96 2.36 1002
PCOS rs2272046 12 66.2 HMGA2 A C 0.7 1.95  10 21 15 0.02 0.9 0.62–1.31 6.09 1001 0.95 NA NA NA NA NA 6.09 1001
PCOS rs4784165 16 52.3 TOX3 T G 1.15 3.64 10 11 15 0.26 0.94 0.84–1.06 8.92 1001 0.97 NA NA NA NA NA 8.92 1001
PCOS rs2059807 19 7.1 INSR A G 1.14 1.09 108 15 0.61 1.08 0.97–1.20 1.86 1001 Gen 0.63 1.1 0.99–1.23 3.11 1001 Gen 9.63 1002
PCOS rs6022786 20 52.4 SUMO1P1 A G 1.13 1.83 10 9 15 0.57 0.96 0.87–1.06 1.47 1001 0.98 NA NA NA NA NA 1.47 1001
PCOS rs10505648 8 13.7 KHDRBS3 G A 0.52 5.46 108 16 0.52 1.01 0.91–1.12 4.95 1001 Gen 0.52 0.96 0.86–1.07 8.51 1001 Gen 6.88 1001
CI, conﬁdence interval; EAF, effect allele frequency in cases and controls combined; Eff, effect allele; Gen, genotyped; Imp r2, Imputation r2;PCOS, polycystic ovary syndrome; P value, signiﬁcance as
assessed by logistic regression for Stage 1 and Stage 2; Pmeta, signiﬁcance as assessed by sample-size weighted two-strata meta-analyses (PCOS Stage 1: 984 cases & 2,964 population control women;
PCOS Stage 2: 1,799 PCOS cases and 1,231 phenotyped reproductively normal control women).
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We focused on this phenotype because it is the one associated
with highest risk for insulin resistance and other metabolic
disorders1,9. Further, B90% of women with NIH phenotype
PCOS have PCOM1,42. PCOM is also a common, age-related
ﬁnding in otherwise reproductively normal women5,42.
Nevertheless, even in the absence of hormonal abnormalities,
PCOM appear to have intrinsic abnormalities in folliculogenesis2
and gonadotropin responsiveness6. PCOS cohorts diagnosed by
Rotterdam criteria are enriched for the phenotypes with PCOM1
and with less severe endocrine abnormalities1,8,9,43. Accordingly,
the inclusion of these additional phenotypes may have
contributed to the differing results between the present and
previous GWAS15,16. In addition, the fact that we did not exclude
PCOM in our control subjects, as was done in the previous Asian
PCOS GWAS15,16, may have limited our power to detect genetic
variation associated with PCOM.
In conclusion, replicated GWAS in Chinese14,15 and European
cohorts36–38 implicate genes modulating gonadotropin action,
LHCGR and FSHR, and secretion, FSHB. These ﬁndings suggest
that gonadotropins play an aetiologic role in PCOS pathogenesis,
analogous to the insights into causative biologic pathways
provided by T2D GWAS implicating b-cell genes and
obesity GWAS implicating neuroendocrine genes modulating
food intake44. Further, these PCOS GWAS studies are
complementary since the Chinese cohort contained additional
Rotterdam phenotypes, whereas our cohort contained only the
NIH phenotype with hyperandrogenism and chronic anovulation.
The Chinese GWAS ﬁndings of associations with the genes
encoding gonadotropin receptors, LHCGR and FSHR, suggest
that ovarian gonadotropin action plays a role in all of the
Rotterdam phenotypes, while our ﬁndings of associations of
FSHB with PCOS and LH levels suggest that gonadotropin
secretion drives the accompanying hormonal derangements of
hyperandrogenism and anovulation. Further genetic analyses
stratiﬁed by Rotterdam phenotype are warranted. In addition,
there was a common 9q22.32 PCOS locus in the Chinese and
European cohorts, suggesting shared susceptibility variants in
these ethnically diverse populations. As human populations
ancestral to Chinese and Europeans diverged from Africans
B60,000 years ago45,46, the 9q22.32 region may harbour an
evolutionarily conserved genetic susceptibility factor for PCOS47.
Studies in African ancestry PCOS populations should provide
further insight into the evolutionary history of this disorder.
Methods
Subjects. Nine-hundred eighty-four PCOS cases and 2,964 population controls
(Stage 1), followed by replication (Stage 2) in 1,799 PCOS cases and 1,231
phenotyped reproductively normal control women were studied. An additional
replication (Stage 3) of the top variant from each region with Po5 10 6
(N¼ 24) was performed in 217 PCOS cases and 1,335 1958 British Birth Cohort
(that is, controls) samples. The study was approved by theInstitutional Review
Board of Northwestern University Feinberg School of Medicine as well as by the
Institutional Review Boards of the study investigators’ institutions (Institutional
Review Boards of Brigham and Women’s Hospital, Carolinas Medical Centre,
Cedars-Sinai Medical Centre, Pennsylvania State Milton S. Hershey Medical
Centre, Magee-Womens Hospital, Medical College of Wisconsin, Massachusetts
General Hospital, University of Pennsylvania, Stanford University, University of
Alabama at Birmingham, University of Chicago, University of Colorado at Denver,
University of Michigan, University of Medicine and Dentistry of New Jersey,
University of Texas Health Science Centre, University of Texas Health Science
Centre at San Antonio, University of Vermont, Virginia Commonwealth
University, Wayne State University; the Research Ethics Committee of Athens
University Medical School; and the North Thames Multicenter Research Ethics
Committee). All subjects were Caucasians of European ancestry and gave written
informed consent before study. Subjects providing samples for the NUgene DNA
biorepository consented to the use of their deidentiﬁed clinical data and DNA
samples by third party investigators48.
PCOS subjects were ages 13–45 years (Table 1). Subjects in the discovery cohort
(Supplementary Data 9) were recruited by the authors (A.D., R.S.L., D.A.E.) and
the Reproductive Medicine Network (RMN) for the Pregnancy in Polycystic Ovary
Syndrome (PPCOS)I study49. PCOS subjects (Supplementary Data 10) were
recruited by the same authors, the RMN PPCOSII study50, as well as by
collaborations with PCOS research centres across the United States (C.K.W.,
M.O.G., R.A.) and in Greece (E.D.K., D.P.) for Stage 2 Replication and in the
United Kingdom (T.B., M.M., S.F.) for Stage 3 Replication. PCOS cases fulﬁlled
NIH criteria for PCOS1. Cases fulﬁlling these criteria also meet the Rotterdam and
Androgen Excess Society criteria for PCOS1. The cases had hyperandrogenism
(clinical and/or biochemical) and chronic anovulation (eight or fewer menses per
year) with exclusion of other hyperandrogenic disorders in the differential
diagnosis, such as non-classical adrenal 21-hydroxylase deﬁciency1. Ovarian
morphology was not a criterion for the diagnosis as it is a non-speciﬁc ﬁnding that
does not correlate with the endocrine phenotype5,42.
Control DNA samples for the discovery cohort came from women self-
identiﬁed as ‘white,’ age 18-97 years collected by the NUgene DNA bank48. The
samples were selected from women with data on body weight, height and age.
Control women in the Stage 2 replication cohort were reproductively normal
women, ages 15–45 years, with regular menses and no hirsutism who were enroled
by the following authors (A.D., R.S.L., C.K.W., E.D-K., D.P., M.O.G., R.A.) as
control subjects for their PCOS studies; the control women had T levels within the
normal range for the assay used by each author. Questionnaire-based reproductive
histories, DNA and EDTA-plasma samples were obtained from 18- to 45-year-old
women who were enroled in the Metabolic Risk Complications of Obesity Genes
project51. Women selected had regular menses and were not receiving oral
contraceptive pills. They had normal total T levels determined using liquid
chromatography-tandem mass spectrometry (LC-MS/MS)52. The details of
recruitment and phenotyping of the discovery and replication cohort PCOS cases
and the replication cohort control women have been reported previously (see
references in Supplementary Data 11). Control women in the UK replication
cohort (Stage 3) were from the 1958 British Birth Cohort (58BBC), and all were of
the age 44-45 years at the time of DNA sample and phenotypic data collection
(BMI and age).
Hormone level assays. The hormone levels used for subject phenotyping and in
the quantitative trait analyses were measured as outlined in Supplementary Data 11
All analyses are adjusted for the study site at which the assay was performed, a
central laboratory was used by the RMN and was, therefore, considered as one site.
Further, some sites changed assay methodology so the analyses were also adjusted
for the assay methodology. The normal range for each assay was established in the
following number of premenopausal, reproductively normal, non-hirsute control
women with regular menses: 98 Cedars Sinai Medical Centre53; 100 University of
Alabama at Birmingham54; 108 University of Athens55; 39 University of Chicago56,
and 75 United Kingdom11.
The normal ranges for the PCOS Family Study were established as reported in
43 premenopausal reproductively normal women with 27–35 day menstrual cycles
and no hirsutism at Penn State Milton S. Hershey Medical Centre10. Since 2006,
the T assay for the PCOS Family Study has been performed at the University of
Virginia Centre for Research in Reproduction Ligand Assay and Analysis Core
using the same assay method (Supplementary Data 11). The normal ranges were
validated in this assay and have been reassessed in an additional cohort of 209
premenopausal reproductively normal women with 27–35 day regular menses and
no clinical symptoms of androgen excess to ensure that the range has not changed.
The normal range for LC-MS/MS T assays used to select control women enroled in
the Metabolic Risk Complications of Obesity Genes project51 was also determined
in this additional cohort of 209 control women. The assays for PPCOSI and
PPCOSII were performed at the University of Virginia Centre for Research in
Reproduction Ligand Assay and Analysis Core. Accordingly, the same normal
range was used at these study sites as was used for the PCOS Family Study T assays
performed in this core.
Stage 1 Discovery GWAS. PCOS cases and NUgene control DNA samples
included in the GWAS phase were genotyped using the Illumina Omni Express
(HumanOmniExpress-12v1_C) at the Centre for Inherited Disease Research
(CIDR), Johns Hopkins University, Baltimore, MD.
GWAS Quality control (QC). Genotypic data that passed initial quality control at
the genotyping centre were released to the PCOS study team who performed
quality control procedures of the data following recommendations from the
GENEVA57 and eMERGE58,59 consortia, in which we were involved. Speciﬁcally,
we removed poorly performing samples or SNPs based on misspeciﬁed sex,
chromosomal anomalies, unintended sample duplicates, sample relatedness, low
call rate, high number of Mendelian errors, departures from Hardy–Weinberg
equilibrium, duplicate discordance, sex differences in heterozygosity and low minor
allele frequencies as detailed in Supplementary Data 12 and 13.
Ancestry. To investigate population structure, we used principal components
analysis (PCA) in EIGENSTRAT (http://genepath.med.harvard.edu/Breich/Soft-
ware.htm), essentially as described by Price et al.60 We used PCA for two purposes:
to identify population group outliers and to include as covariates in the statistical
model used for association testing to account for population structure. Initially, we
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analysed all unduplicated PCOS GWAS study samples separately, along with
HapMap (Phase 3 CEU, CHB, JPT and YRI) to detect of population outliers among
the study. We started with a set of 703,171 autosomal SNPs with missing call rate
o1%. From this pool of overlapping SNPs, we selected a subset through two
rounds of LD pruning using the pair-wise genotypic correlation method in
PLINK61 (http://pngu.mgh.harvard.edu/Bpurcell/plink/). In the ﬁrst round, we
removed SNPs in short-range LD using a window size of 50 SNPs with a ﬁve SNP
offset and an r2 threshold of 0.8. The second round of pruning removed SNPs in
long-range LD using a window size equal to the median number. The r2 threshold
was set at 0.8 for the second round of pruning, after which 76,602 SNPs remained
that were also found in HapMap. After exclusion of outlier subjects (34 GWAS
phase and 37 replication phase samples43 s.d. values from the median of the ﬁrst
two principal components), we used the ﬁrst two eigenvectors from the results in
these analyses as covariates in the association tests to adjust for any possible
population structure among the study subjects (Supplementary Fig. 10). The
genomic inﬂation parameter lGC1000 (calculated following de Bakker, et al.62 was
sufﬁciently small (o1.05 in each of the GWAS performed with the different
phenotypes) to suggest that population stratiﬁcation was adequately controlled in
our model and that there was no inﬂation of false positives from this potential
confounder.
Imputation. We performed genotype imputation using IMPUTE263
(https://mathgen.stats.ox.ac.uk/impute/impute_v2.html) and the 1000 Genomes
reference panel64. We used a ‘cosmopolitan’ 1000 Genomes reference panel for
imputation consisting of an intersection of the AFR, EUR, and ASN panels. We
ﬁrst used the strand-checking utility of SHAPEIT v2 (ref. 65) (https://mathgen.
stats.ox.ac.uk/genetics_software/shapeit/shapeit.html) to ensure consistent strand
assignments between the reference data set and the QC cleaned and ﬁltered data
sets, and we subsequently corrected strand and/or removed SNPs where
strandedness could not be resolved. We used a conservative allelic r2 threshold of
0.9 to remove questionable imputed SNPs.
Association tests. The genotype call probabilities from the ﬁltered IMPUTE2
output were used in a logistic regression model between PCOS case–control status
and the genotypes probabilities under an additive model adjusting for BMI, and the
ﬁrst three principal components of ancestry. Similarly, we used a linear regression
model between each of the quantitative reproductive hormone levels (treated as
continuous variables) and the genotype probabilities under an additive model
adjusting for BMI, the ﬁrst three principal components of ancestry, assay site and
assay method. FSH and SHBG were log-transformed to normalize before con-
ducting the association tests. We used the frequentist approach in SNPTEST66
v2.2.0 (https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html) or
ProbABEL67 v0.4.3 to estimate the odds ratio and 95% conﬁdence intervals (PCOS
case/control status), or beta and s.e. values (hormone levels) for each regression
model and assess the signiﬁcance of the association between the SNP and the
phenotype of interest.
Stage 2 Metabochip replication. We attempted replication our top associations
in a second set of 1,799 PCOS cases and 1,231 phenotyped controls by adding
12,921 SNPs (those with Po1 10 5 in the GWAS phase, as well as candidate
SNPs for ancillary studies) as custom content to the Metabochip68. Genotyping was
performed at the Broad Institute Centre for Genotyping and Analysis (CGA),
Cambridge, MA, who released 9,893 of the 12,921 add-on SNPs attempted.
Genotyping QC, assessing ancestry, imputation to 1,000 genomes, and association
tests followed that of the GWAS phase described above. To assess population
substructure in the Stage 2 Replication, we analysed all unduplicated PCOS
replication study samples separately, along with HapMap (Phase 3 CEU, CHB, JPT
and YRI) to detect of population outliers among the study. We started with a set of
197,415 autosomal SNPs with missing call rate o2%. From this pool of
overlapping SNPs, we selected a subset through two rounds of LD pruning using
the pair-wise genotypic correlation method in PLINK. In the ﬁrst round we remove
SNPs in short-range LD using a window size of 50 SNPs with a ﬁve SNP offset and
an r2 threshold of 0.8. The second round of pruning removed SNPs in long-range
LD using a window size equal to the median number. The r2 threshold was set at
0.8 for the second round of pruning after which 53,828 SNPs remained that were
also found in HapMap. After exclusion of outlier subjects (42 s.d. values from the
median of the ﬁrst two principal components) we used the ﬁrst two eigenvectors
from the results in these analyses as covariates in the association tests to adjust for
any possible population structure among the study subjects (Supplementary
Fig. 11).
Stage 3 (UK) Replication. The Illumina Core Exome and Illumina Human
1.2 Million Duo Custom v1_A platforms were used to genotype the UK cases and
controls, respectively. Overlapping variants (N¼ 191,563) were included in the
quality control (QC) and imputation phases. As cases and controls were typed
separately, stringent QC thresholds were applied before and after merging the
case–control data. Pre-imputation QC included exclusion ﬁlters: (i) HWE
P value o0.0001 in cases and controls separately, and HWE P valueo0.01 in the
merged data; (ii) SNP call rateo95% in cases and controls separately; (iii) sample
call rate o95% in cases and controls separately; (iv) differential SNP missingness
between cases and controls in the merged data, P valueo0.01; (v) s.e.410 in
pre-imputation logistic regression analysis; (vi) MAFo1% in the ﬁnal clean
merged data. In addition, related individuals and ethnic outliers were detected and
excluded using PLINK pairwise IBD estimation and multidimensional scaling
analysis (MDS).
Pre-phasing and imputation were performed using SHAPEIT and IMPUTE2
with the 1000 Genomes March 2012 (v3) reference panel, respectively. SNPTEST
was used for association analyses. Case–control and quantitative analyses included
C1 from the PLINK MDS analysis as a covariate to adjust for population
stratiﬁcation. Variants with info scoreo0.4, s.e.o0 and s.e.410, and P-valueo0
were excluded from the association results.
Meta-analysis. The betas and s.e. values were combined across the GWAS and
replication cohorts using meta-analysis under a ﬁxed effects model weighting each
strata by sample size. METAL69 (http://www.sph.umich.edu/csg/abecasis/metal/
index.html) calculates a z-statistic, which summarizes the magnitude and direction
of effect for the association of a reference allele selected at each marker. After
aligning the SNPTEST output from each of the four cohorts to the same reference
allele, a weighted sum of the individual cohort results is used to calculate an overall
z-statistic and P value. The square root of the cohort speciﬁc sample size is used as
the proportional weight, and these squared weights sum to 1.
Predicting transcription activity of the GWAS loci. To investigate the tran-
scriptional potential of the primary GWAS loci identiﬁed in the dichotomous and
quantitative trait analyses, we examined the histone mark patterns and mRNA
levels for each locus using ENCODE ChIP-Seq data, RNASeq (http://geno-
me.ucsc.edu) and GNF Expression Atlas 1 Human Data on Affy U95 Chips
http://genome.ucsc.edu). A broad tissue distribution was tested for the expression
array and the RNAseq. Multiple tissues contribute to the PCOS phenotype.
Although there are no ChiP-Seq ENCODE results from any ovarian tissues, PCOS
is also associated with substantial metabolic abnormalities1. These abnormalities
include defects in adipocyte, skeletal muscle and hepatic insulin action as well as
pancreatic b-cell dysfunction 1. Our analysis included on metabolic tissues affected
in PCOS (adipose nuclei, adult liver, pancreatic islets and skeletal muscle).
We present chromatin Immunoprecipitation sequencing (ChIP-Seq) results
from Encyclopaedia of DNA Elements (ENCODE) Consortium Roadmap
Epigenomics Consortium [(http://www.roadmapepigenomics.org/data) for six
histone marks (H3K27m3, H3K36m3, H3K4m1, H3K4m3, H3K9ac and H3K9m3)
in four human tissues that are potentially relevant to PCOS (adipose nuclei, adult
liver, pancreatic islets and skeletal muscle)]. H3K27m3 histone mark is the tri-
methylation of lysine 27 of the H3 histone protein and is associated with
facultatively expressed genes (www.epigentek.com). H3K36m3, tri-methylation of
lysine 36 of H3, is associated with actively transcribed genes (www.epigentek.com).
H3K4m1, mono-methylation of lysine 4 of H3, is associated with enhancers and
with DNA regions downstream of transcription starts (www.epigentek.com).
H3K4m3, tri-methylation of lysine 4 of H3, is associated with promoters that are
active or poised to be activated (www.epigentek.com). H3K9ac, acetylation of lysine
9 of H3, is found in actively transcribed promoters (www.epigentek.com).
H3K9m3, tri-methylation of lysine 9 of H3, in contrast is found in constitutively
repressed genes (www.epigentek.com). We considered a methylation mark to active
if there is more than one peak with a height greater than 5 times background
height.
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